Regional Accountable Entities (19-20)
This issue brief provides an overview of Regional Accountable Entities, organizations responsible for coordinating the physical and behavioral health care of the state’s Medicaid members.
First Regular Session | 74th General Assembly
Colorado General AssemblyThis issue brief provides an overview of Regional Accountable Entities, organizations responsible for coordinating the physical and behavioral health care of the state’s Medicaid members.
This memorandum provides an overview of broadband internet service programs in Colorado, including the Colorado High Cost Support Mechanism; state grant programs and other state efforts; local governments’ ability to provide broadband; and related recent legislation.
This memorandum addresses patient access to experimental treatments, including access to clinical trials, participation in the U.S. Food and Drug Administration’s Expanded Access (Compassionate Use) Program, and access to treatments under Colorado’s Right to Try Act. Additionally, this...
This issue brief addresses the state’s emergency mental health hold procedure, which allows for a person to be involuntarily held for a 72-hour period of treatment and evaluation if he or she appears to have a mental illness and, due to the mental illness, appears to be an imminent danger to...
This memorandum presents the impact of Senate Bill 17-267 on special districts that previously assessed sales taxes on retail marijuana transactions.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its September 2017 meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its September 2017 meeting.
Presented to the Opioid and Other Substance Use Disorder Interim Study Committee at its September 2017 meeting.
Presented to the Opioid and Other Substance use Disorders Interim Study Committee at its September 2017 meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its September 2017 meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its September 2017 meeting.